21. HIV Prevention
Thursday, October 8, 2015: 8:30 AM-10:00 AM
Room: 30--ABCDE

Learning Objectives:

At the conclusion of this session, participants will be able to:

  • summarize progress in HIV preventive vaccines
  • describe the latest approaches and impact of universal HIV testing and treatment programs
  • discuss lessons learned from microbicide clinical trials

Target Audience: Researchers, Public health practitioners, Members-in-training, Infectious diseases physicians, Infectious diseases pediatricians, HIV specialists, HIV clinicians, Clinicians, Academicians

Tracks: HIV-STD-TB, Adult ID

Moderators:  Pablo Tebas, MD, FIDSA, University of Pennsylvania and Colleen Kelley, MD, MPH, Emory University

8:30 AM
Advances in Preventive Vaccines
Scott Hammer, MD, FIDSA

9:00 AM
Universal Test and Treat
Myron Cohen, MD, FIDSA

9:30 AM
Microbicides—Where Are We?
Jeanne Marrazzo, MD, MPH, FIDSA

CME Credits: Maximum of 1.5 hours of AMA PRA Category 1 CreditTM

ACPE Credits: ACPE 1.5 knowledge-based contact hours (0.15 CEU) of pharmacy CE

ACPE Number: 0221-9999-15-150-L02-P


P. Tebas, Merck: Consultant , Consulting fee
Glaxo: Consultant , Consulting fee

C. Kelley, None

See more of: Symposium

Findings in the abstracts are embargoed until 12:01 a.m. PDT, Wednesday Oct. 7th with the exception of research findings presented at the IDWeek press conferences.